ArticleJournal of nephrology2017
Profiling risk for acute rejection in kidney transplantation: recipient age is a robust risk factor.
Article in Journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Tacrolimus Monotherapy is Safe in Immunologically Low-Risk Kidney Transplant Recipients: A Randomized-Controlled Pilot Study.Transplant international : official journal of the European Society for Organ Transplantation · 2022Trial
- Infections after kidney transplantation. Does age matter?Clinical transplantation · 2019Trial
- Prognostic impact of rejection and chronicity index on long-term graft outcomes in pediatric kidney transplant recipients.Frontiers in immunology · 2026Article
- T Cell immune reconstitution after allo-HSCT: key factors and implications.Blood science (Baltimore, Md.) · 2025Review
- Evaluating the Role of Basiliximab Induction in Simultaneous Liver-Kidney Transplantation: A Multicenter Propensity-Score-Matched Analysis.Antibodies (Basel, Switzerland) · 2025Article
- Senescence-induced p21Cell discovery · 2025Article
- Necessity of induction agent modification for old age kidney transplant recipients.Kidney research and clinical practice · 2025Article
- Precision in Immune Management: Balancing Steroid Exposure, Rejection Risk, and Infectious Outcomes in Adult Kidney Transplant Recipients.Journal of personalized medicine · 2024Article
- Article
- Impact of Immunosenescence in Older Kidney Transplant Recipients: Associated Clinical Outcomes and Possible Risk Stratification for Immunosuppression Reduction.Drugs & aging · 2024Review
- Donor hepatitis C status is not associated with an increased risk of acute rejection in kidney transplantation.Surgery in practice and science · 2024Article
- The aging of the immune system and its implications for transplantation.GeroScience · 2023Review
- The Korean Organ Transplantation Registry (KOTRY): an overview and summary of the kidney-transplant cohort.Kidney research and clinical practice · 2022Article
- Delayed Graft Function Under the Microscope: Surveillance Biopsies in Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- Expression of Senescence Marker TIGIT Identifies Polyfunctional Donor-Reactive CD4+ T Cells Preferentially Lost After Kidney Transplantation.Frontiers in immunology · 2021Article
- Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching.Frontiers in immunology · 2020Review
- The role of senescence of bone marrow cells in acute kidney injury.Kidney research and clinical practice · 2019Article
- Successful Renal Transplantation between Identical Twins with Very Brief Immunosuppression.Case reports in transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Careful management of immunosuppression is paramount to prevent acute rejection in kidney transplantation. We studied a cohort of 139,875 kidney transplant recipients from the Organ Procurement and Transplantation Network (OPTN) database between 2002 and 2013. We confirmed the analysis with a cohort of 35,277 who received thymoglobulin induction with tacrolimus maintenance, and a third cohort of 12,161 recipients who received basiliximab induction with tacrolimus maintenance. We performed multivariate logistic regression analyses on data from all three cohorts and identified independent risk factors for treated acute rejection at 1 year. Recipient age was a robust risk factor for rejection in all three cohorts in a dose response pattern. Young age (18-25 years) was among the strongest risk factors for rejection in all three cohorts; thymoglobulin cohort: OR 1.87 (1.59-2.19); basiliximab cohort: OR 2.41 (1.89-3.05); and inclusive cohort: OR 1.97 (1.83-2.12). The opposite was true for old age (65-69 years); thymoglobulin cohort: OR 0.69 (0.59-0.81); basiliximab cohort: OR 0.77 (0.62-0.96); and inclusive cohort: OR 0.75 (0.70-0.80). This study is unique because it is the largest and most comprehensive multivariate analysis that demonstrates recipient age is a robust risk factor for acute rejection in an inverse dose response pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.